BiotechTube

versus hydroxychloroquine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Systemic Lupus Erythematosus

Conditions

Systemic Lupus Erythematosus

Trial Timeline

Jun 1, 2007 → Jan 1, 2011

NCT ID
NCT00413361

About versus hydroxychloroquine

versus hydroxychloroquine is a approved stage product being developed by Sanofi for Systemic Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT00413361. Target conditions include Systemic Lupus Erythematosus.

What happened to similar drugs?

9 of 20 similar drugs in Systemic Lupus Erythematosus were approved

Approved (9) Terminated (4) Active (8)
✅Baricitinib + CyclophosphamideEli LillyApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅EfalizumabMerckApproved
✅AmbrisentanGilead SciencesApproved
✅BMS-986165Bristol Myers SquibbApproved
✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00413361ApprovedCompleted

Competing Products

20 competing products in Systemic Lupus Erythematosus

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 2
35
E6742EisaiPhase 1/2
32
KHK4827Kyowa KirinPhase 1
29
KHK4827 + PlaceboKyowa KirinPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + CyclophosphamideEli LillyApproved
47
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29